European Society for Medical Oncology Congress | Conference

Possible Association Noted Between Tumor Immunogenicity and Survival Outcomes in HR+, HER2+ Early Breast Cancer Following Neoadjuvent T-DM1 De-Escalation
September 20, 2021

Investigators believe the use of biomarkers can determine the results of de-escalated neoadjuvant T-DM1 in HR-positive/HER2-positive early breast cancer.

Treatment With Adjuvant Atezolizumab Yields Improved Outcomes in Stage II-IIIA PD-L1–Positive NSCLC
September 20, 2021

Patients with stage II to IIIA non–small cell lung cancer experienced an improvement in disease-free survival and time to locoregional and distant relapse after being treated with adjuvant atezolizumab.

Sunitinib Treatment Improved Survival for Malignant Pheochromocytoma and Paraganglioma
September 20, 2021

Treatment with sunitinib resulted in improved efficacy results in the FIRSTMAPPP trial for patients with malignant pheochromocytoma and paraganglioma.